Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Uluru Co., Ltd. (3979:JPX), powered by AI.
Uluru Co., Ltd. is currently trading at ¥403. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Uluru Co., Ltd. on Alpha Lenz.
View Uluru Co., Ltd.'s valuation metrics on Alpha Lenz.
“Uluru Co., Ltd.'s ROE is 21.9%. Explore profitability and growth together.”
Ask for details →Uluru Co., Ltd. is a prominent entity in the pharmaceutical industry, recognized for its innovative drug delivery technologies. Specializing in advanced research and development, the company's core mission is to enhance patient outcomes through novel medical solutions. Uluru Co., Ltd. focuses on creating drug delivery systems that optimize therapeutic efficacy and patient compliance. Its major contributions include the development of transmucosal and adhesive technologies that provide targeted, controlled release of medications. The company significantly impacts the healthcare industry, particularly in pain management and wound care sectors. Through strategic partnerships and continuous innovation, Uluru Co., Ltd. maintains a vital role in meeting the global demand for improved medical treatments.
“Uluru Co., Ltd.'s ROE is 21.9%. Explore profitability and growth together.”
Ask for details →Uluru Co., Ltd. (ticker: 3979) is a company listed on JPX in the Technology sector (Information Technology Services). It has approximately 268 employees.
The current price is 403 with a P/E ratio of -x and P/B of -x.
ROE is 21.93% and operating margin is 12.03%. Annual revenue is $7.8B.